​

Processa Pharmaceuticals (PCSA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PCSA Stock Forecast

Processa Pharmaceuticals (PCSA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $9.00 and a low of $9.00. This represents a 2712.50% increase from the last price of $0.32.

- $1 $2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $9 Low: $9 Last Closed Price: $0.32

PCSA Stock Rating

Processa Pharmaceuticals stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

PCSA Price Target Upside V Benchmarks

TypeNameUpside
StockProcessa Pharmaceuticals2712.50%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.32$0.32$0.32
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 251-1--2
Sep, 251-1--2
Aug, 251-1--2
Jul, 251-1--2
Jun, 251-1--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 19, 2022Maxim Group$9.00$3.18183.02%2712.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 02, 2025H.C. WainwrightBuyBuyhold
Oct 03, 2024H.C. WainwrightBuyBuyhold
Jan 12, 2023Maxim GroupBuyBuyhold
Aug 03, 2021OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-10 $-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-8.48----
Avg Forecast$-8.80$-4.05$-2.16$-6.20$-5.40
High Forecast$-8.49$-4.05$-2.16$-6.20$-5.40
Low Forecast$-9.11$-4.05$-2.16$-6.20$-5.40
Surprise %-3.64%----

Revenue Forecast

$10M $11M $12M $13M $14M $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast--$14.91M$10.01M$10.36M
High Forecast--$14.91M$10.01M$10.36M
Low Forecast--$14.91M$10.01M$10.36M
Surprise %-----

Net Income Forecast

$-12M $-10M $-8M $-6M $-4M $-3M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-11.12M$-11.85M---
Avg Forecast$-11.54M$-5.31M$-2.83M$-8.13M$-7.08M
High Forecast$-11.13M$-5.31M$-2.83M$-8.13M$-7.08M
Low Forecast$-11.95M$-5.31M$-2.83M$-8.13M$-7.08M
Surprise %-3.64%123.09%---

PCSA Forecast FAQ

Is Processa Pharmaceuticals stock a buy?

Processa Pharmaceuticals stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Processa Pharmaceuticals is a favorable investment for most analysts.

What is Processa Pharmaceuticals's price target?

Processa Pharmaceuticals's price target, set by 5 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $9 at the low end to $9 at the high end, suggesting a potential 2712.50% change from the previous closing price of $0.32.

How does Processa Pharmaceuticals stock forecast compare to its benchmarks?

Processa Pharmaceuticals's stock forecast shows a 2712.50% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Processa Pharmaceuticals over the past three months?

  • October 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Processa Pharmaceuticals’s EPS forecast?

Processa Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.16, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-6.2 in 2026, and $-5.4 in 2027.

What is Processa Pharmaceuticals’s revenue forecast?

Processa Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $14.91M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10.01M, and $10.36M for 2027.

What is Processa Pharmaceuticals’s net income forecast?

Processa Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-2.833M, representing a -76.09% decrease from the reported $-11.85M in 2024. Projections indicate $-8.132M in 2026, and $-7.082M in 2027.